



Final Appraisal Recommendation

Advice No: 3015 – October 2015

Fosfomycin (Fomicyt®) 40 mg/ml powder for solution for infusion

Limited submission by Nordic Pharma UK Ltd

Recommendation of AWMSG

Fosfomycin (Fomicyt®) is recommended as an option for use within NHS Wales for the treatment of the following infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract infections; bacterial meningitis; and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

Fosfomycin (Fomicyt®) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of the infections listed above, or when these alternative antibacterial agents have failed to demonstrate efficacy.

Additional note(s):

- Fosfomycin (Fomicyt®) is appropriate for specialist only prescribing on the advice of a microbiologist.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2710), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Nordic Pharma UK Ltd
Date of first issue	October 2015
Last reviewed	April 2019



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3015:
Fosfomicin (Fomicyt[®]) 40 mg/ml powder for solution for infusion. October 2015.

